Conversely, only a modest reduction of pS6, PTEN, and stathmin phosphorylation emerged in a window of opportunity (WoO) trial evaluating MK-2206 in early BC patients, irrespectively of their intrinsic subtype (Kalinsky et al., 2018). Here, PTEN is linked to breast cancer.